Users Online: 113
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 

 Table of Contents  
Year : 2014  |  Volume : 3  |  Issue : 3  |  Page : 189

Expected efficacy of HPV vaccine in prevention of cervix cancer in Thailand

1 Sanitation 1 Medical Academic Center, Bangkok, Thailand
2 Visiting Professor, Hainan Medical University, China; Visiting Professor, Faculty of Medicine, University of Nis, Serbia; Adjunct Professor, Joseph Ayobabalola University, Nigeria; Professor, Senior Expert, Public Health Curriculum Surin Rajabhat University, Surin, Thailand

Date of Web Publication15-Jul-2014

Correspondence Address:
Beuy Joob
Sanitation 1 Medical Academic Center, Bangkok, Thailand

Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2278-330X.136821

Rights and Permissions

How to cite this article:
Joob B, Wiwanitkit V. Expected efficacy of HPV vaccine in prevention of cervix cancer in Thailand. South Asian J Cancer 2014;3:189

How to cite this URL:
Joob B, Wiwanitkit V. Expected efficacy of HPV vaccine in prevention of cervix cancer in Thailand. South Asian J Cancer [serial online] 2014 [cited 2020 Jan 24];3:189. Available from:

Dear Editor,

The HPV vaccine is the first human cancer vaccine. It is recommended as the primary prevention for cervix cancer. [1] It was mentioned the available HPV vaccine is safe and "HPV vaccination will result in approximately 70% reduction of cervical cancers. [2]" In Thailand, the HPV vaccine is presently available and recommended for sexually active females. In fact, the trial of the HPV before official launch was performed in several setting including Thailand. [3] However, the vaccination is presently not successfully and there are many obstacles. The big problem is due to the cost of vaccine. According to the report by Songthap et al., "willingness to pay was relatively low. [4]" Nevertheless, Termrungruanglert et al., found that the HPV vaccine was cost-effective in Thailand. [5] An interesting remained question is still left for the efficacy of the vaccine in each individual. As already noted, the reduction of cancer can be expected in only seven-tenths of all cases and the protection is HPV-type specific. The present vaccine covers only 4 HPV types (6,11,16,18). Here, the authors tried to estimated expected efficacy of vaccine in each individual. According to the previous study on HPV type in Thai females with cervix cancer, only 71% of the patients had the HPV in either one of the mentioned 4 HPV types (6, 11, 16, 18). [6] Based on basic probability principle, the efficacy of vaccine for protection of an individual should be equal to "0.7 × 0.71 = 0.497." This means less than half of vaccinated females can be expected for successful prevention. In fact, there are also other factors that can also decreased the protective ability of the vaccine such as the vaccination technique, complication to vaccination program, etc. As Henderson et al., noted, "clearer information is needed concerning the incomplete protection offered by the vaccine, and that cervical screening will still be required. [7]"

  References Top

1.Altinbas SK, Tapisiz OL. Human papillomavirus, vaccines, and protection from cervical cancer. Saudi Med J 2012;33:1270-7.  Back to cited text no. 1
2.Tomljenovic L, Spinosa JP, Shaw CA. Human papillomavirus (HPV) vaccines as an option for preventing cervical malignancies: (how) effective and safe? Curr Pharm Des 2013;19:1466-87.  Back to cited text no. 2
3.Muñoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: A randomised, double-blind trial. Lancet 2009;373:1949-57.  Back to cited text no. 3
4.Songthap A, Pitisuttithum P, Kaewkungwal J, Fungladda W, Bussaratid V. Knowledge, attitudes, and acceptability of a human papilloma virus vaccine among students, parents and teachers in Thailand. Southeast Asian J Trop Med Public Health 2012;43:340-53.  Back to cited text no. 4
5.Termrungruanglert W, Havanond P, Khemapech N, Lertmaharit S, Pongpanich S, Khorprasert C, et al. Cost and effectiveness evaluation of prophylactic HPV vaccine in developing countries. Value Health 2012;15:S29-34.  Back to cited text no. 5
6.Chinchai T, Chansaenroj J, Swangvaree S, Junyangdikul P, Poovorawan Y. Prevalence of human papillomavirus genotypes in cervical cancer. Int J Gynecol Cancer 2012;22:1063-8.  Back to cited text no. 6
7.Henderson L, Clements A, Damery S, Wilkinson C, Austoker J, Wilson S, HPV Core Messages Writing Group. A false sense of security′? Understanding the role of the HPV vaccine on future cervical screening behaviour: A qualitative study of UK parents and girls of vaccination age. J Med Screen 2011;18:41-5.  Back to cited text no. 7


Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  In this article

 Article Access Statistics
    PDF Downloaded204    
    Comments [Add]    

Recommend this journal